Found: 5
Select item for more details and to access through your institution.
An Evidence-Based Rationale for Dose De-escalation of Subcutaneous Atezolizumab.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 5, p. 779, doi. 10.1007/s11523-024-01087-4
- By:
- Publication type:
- Article
Model-Informed Development of a Cost-Saving Dosing Regimen for Sacituzumab Govitecan.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 5, p. 789, doi. 10.1007/s11523-024-01075-8
- By:
- Publication type:
- Article
Increased Tacrolimus Exposure in Kidney Transplant Recipients With COVID-19: Inflammation-Driven Downregulation of Metabolism as a Potential Mechanism.
- Published in:
- Transplant International, 2022, v. 35, n. 5, p. 165, doi. 10.3389/ti.2022.10269
- By:
- Publication type:
- Article
Tacrolimus 4‐hour monitoring in liver transplant patients is non‐inferior to trough monitoring: The randomized controlled FK04 trial.
- Published in:
- Clinical Transplantation, 2022, v. 36, n. 12, p. 1, doi. 10.1111/ctr.14829
- By:
- Publication type:
- Article
A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer.
- Published in:
- Targeted Oncology, 2023, v. 18, n. 3, p. 441, doi. 10.1007/s11523-023-00958-6
- By:
- Publication type:
- Article